Trials / Recruiting
RecruitingNCT06158386
Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma
A Multicenter, Prospective, Single-arm Clinical Study on the Treatment of Refractory/Relapsed Follicular Lymphoma (R/RFL) With Chidamide Combined With Linperlisib
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 33 (estimated)
- Sponsor
- The First Affiliated Hospital of Xiamen University · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To observe the safety and efficacy of Chidamide combined with Linperlisib in the treatment of refractory and relapsed follicular lymphoma.
Detailed description
This is a Phase 2, open-label clinical trial study that aims to evaluate the efficacy (eg. Complete response, Overall Survival, Progression Free Survival) and adverse effects of Chidamide combined with Linperlisib in the treatment of refractory and relapsed follicular lymphoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Chidamide combined with Linperlisib | Specified dose on specified days: Cedarbenzamide (C) 20mg orally twice weekly, Limplica (L) 80mg once daily, 2 weeks on 2 weeks off, Repeat on day 28. |
Timeline
- Start date
- 2023-11-22
- Primary completion
- 2027-12-31
- Completion
- 2027-12-31
- First posted
- 2023-12-06
- Last updated
- 2025-02-19
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06158386. Inclusion in this directory is not an endorsement.